RxDoctor Payments Data

Tara Holmes

Internal Medicine · Winchester, VANPI 1356389613

Payments from drug & device makers

$765in general payments, 2019–2025

Across 27 payments — averaging $28.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$321
  • Coloplast$136
  • Sumitomo Pharma America, Inc.$78
  • Tolmar, Inc.$57
  • Progenics Pharmaceuticals, Inc.$28
  • Tolmar Pharmaceuticals, Inc.$21
  • plus $122 from 7 others

What the payments were for

  • Food & beverage$765100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$765 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$99,590
Medicare patients
611
Services billed
4,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron64$49,437
GemtesaVibegron19$19,698
Potassium Citrate ErPotassium Citrate51$5,606
Tamsulosin Hcl214$3,466
Silodosin25$2,298
Oxybutynin Chloride ErOxybutynin Chloride64$1,573
Finasteride127$1,512
Estradiol18$1,249
Trimethoprim27$917
Cephalexin98$575
Alfuzosin Hcl ErAlfuzosin Hcl23$447
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim44$347
Oxybutynin Chloride16$242
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$121
Doxycycline Hyclate14$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$20$49,43764 claims
Sumitomo Pharma America, Inc.Gemtesa$78$19,69819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →